Company Profile For Ranbaxy Laboratories Ltd

Ranbaxy Laboratories Limited is a pharmaceutical industry. The Company manufactures and markets Pharmaceuticals; value added generic and branded generics. The Company’s product basket encompasses a wide therapeutic mix covering a majority of the chronic and acute and lifestyle disease segments such as cardiovascular, central nervous system, respiratory, dermatology, orthopedics, nutririonals and urology segments. The Company's products are: Simvastatin, Amoxy+Clav Potas Coin, Amoxycillin, Ciprofloxacin, Isotretinon, Cephalexin, Ketorolac Tromethamine, Cefaclor, Clarithromycin and Cefuroxime Axetil. The company’s segment includes: pharmaceuticals, which comprises manufacture and trading of formulations, active pharmaceuticals ingredients (API) and intermediate, generics, drug discovery and consumer health care products; Other businesses comprise of rendering of financial services. In November 2008, Daiichi Sankyo completed the acquisition of 63.92% interest in the Company.

BRIEF: For the fiscal year ended 31 December 2008, Ranbaxy Laboratories Limited's revenues increased 11% to RS76.92B. Net loss totaled RS9.51B vs. an income of RS7.75B. Revenues reflect increased income from pharmaceuticals business segment and higher income from Europe market. Net loss reflects higher consumption of raw materials, an increase in legal & professional charge and higher advertising & sales promotion expenses.